Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Biomedical Research Alliance

Neither a doctor nor a teaching hospital

Research payments

$3,223,755

1,076 payments

Through program year 2025, Biomedical Research Alliance is reported as receiving $3,223,755 in research payments, across 1,076 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $147,623 67
2024 Research $112,887 65
2023 Research $301,600 130
2022 Research $631,364 181
2021 Research $805,846 224
2020 Research $295,882 130
2019 Research $928,554 279

Breakdown

Who paid Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $579,624 91 payments
  2. United Therapeutics Corporation $392,846 179 payments
  3. Pharmacyclics LLC, An AbbVie Company $367,291 121 payments
  4. GlaxoSmithKline, LLC. $175,041 97 payments
  5. Sanofi US Services Inc. $167,585 58 payments
  6. SK Life Science, Inc. $165,348 93 payments
  7. Boston Scientific Corporation $138,437 55 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $123,829 49 payments
  9. Jazz Pharmaceuticals Inc. $109,830 26 payments
  10. ViiV Healthcare Company $103,364 37 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1B/2 Study of Tak-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced Or Metastatic Solid Tumors $489,616 33 payments
  2. Pcyc-1142-Ca $191,682 20 payments
  3. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $158,308 68 payments
  4. Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) $151,179 47 payments
  5. An Open-Label Study of Defibrotide for the Prevention of Acute Graft-Versus-Host-Disease (Agvhd) $97,562 14 payments
  6. A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarl $96,989 47 payments
  7. U31402-A-J101 $91,066 17 payments
  8. Study name not reported $91,066 26 payments
  9. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Vib7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus $78,950 2 payments
  10. A Phase Iiib, Randomized, Multicenter, Active-Controlled, Parallel-Gro $72,684 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record